Serena Williams Reveals Use of Weight-Loss Drugs for Post-Pregnancy Health
Serena Williams has openly shared her use of GLP-1 medication to manage post-pregnancy weight, losing 31 pounds in eight months, driven by concerns over her family's diabetes history.
Overview
Serena Williams has publicly disclosed her use of weight-loss drugs to address post-pregnancy weight challenges, joining other celebrities in discussing such medications.
Williams has consistently used a GLP-1 medication since April, resulting in a significant 31-pound weight loss over an eight-month period.
Her decision to use the medication is partly influenced by a family history of diabetes, a condition that poses a higher risk for African American adults.
GLP-1 brands, including Ozempic, Wegovy, and Mounjaro, function by mimicking a gut hormone to reduce appetite and aid in weight management.
Beyond weight loss, Wegovy, a GLP-1 drug, is FDA-approved to reduce the risk of heart attack and stroke in overweight or obese adults, including those with heart disease.
Analysis
Center-leaning sources cover this story neutrally, focusing on factual reporting of Serena Williams's announcement. They present her reasons for taking weight loss medication, detail her campaign to normalize their use, and provide objective information about GLP-1 drugs and other celebrities using them, without injecting editorial bias.